Qiagen NV (QGEN) Stock Rating Reaffirmed by Commerzbank AG
A number of other equities research analysts have also commented on the stock. Deutsche Bank AG reissued a buy rating on shares of Qiagen NV in a report on Monday, June 6th. Zacks Investment Research raised shares of Qiagen NV from a sell rating to a hold rating in a report on Monday, July 4th. HSBC raised shares of Qiagen NV from a hold rating to a buy rating in a report on Monday, August 1st. Morgan Stanley reissued a buy rating on shares of Qiagen NV in a report on Wednesday, June 8th. Finally, TheStreet raised shares of Qiagen NV from a hold rating to a buy rating in a report on Friday, July 29th. Seven research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of $25.36.
Qiagen NV (NASDAQ:QGEN) opened at 26.45 on Friday. Qiagen NV has a 12 month low of $19.94 and a 12 month high of $28.04. The company’s 50-day moving average is $26.75 and its 200-day moving average is $23.37. The stock has a market capitalization of $6.19 billion, a P/E ratio of 52.90 and a beta of 0.90.
Qiagen NV (NASDAQ:QGEN) last issued its quarterly earnings data on Thursday, July 28th. The company reported $0.24 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.01. Qiagen NV had a net margin of 9.13% and a return on equity of 9.21%. The firm had revenue of $334.40 million for the quarter, compared to analyst estimates of $326.73 million. During the same quarter in the prior year, the firm earned $0.26 EPS. The company’s revenue was up 4.7% on a year-over-year basis. Equities analysts anticipate that Qiagen NV will post $1.09 earnings per share for the current year.
A number of hedge funds have recently made changes to their positions in QGEN. Fuller & Thaler Asset Management Inc. bought a new stake in shares of Qiagen NV during the second quarter valued at approximately $116,000. First Mercantile Trust Co. bought a new stake in shares of Qiagen NV during the second quarter valued at approximately $126,000. Societe Generale bought a new stake in shares of Qiagen NV during the second quarter valued at approximately $152,000. SG Americas Securities LLC increased its stake in shares of Qiagen NV by 9.9% in the second quarter. SG Americas Securities LLC now owns 6,977 shares of the company’s stock valued at $152,000 after buying an additional 629 shares during the period. Finally, Royal Bank of Canada increased its stake in shares of Qiagen NV by 25.2% in the first quarter. Royal Bank of Canada now owns 7,712 shares of the company’s stock valued at $173,000 after buying an additional 1,553 shares during the period. Hedge funds and other institutional investors own 58.76% of the company’s stock.
About Qiagen NV
QIAGEN N.V. (QIAGEN) is a holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems.
Receive News & Ratings for Qiagen NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen NV and related companies with MarketBeat.com's FREE daily email newsletter.